5-alpha reductase inhibitors

DRUG2 trials

Sponsors

GlaxoSmithKline, Chinese PLA General Hospital

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD)Benign Prostatic Hypertrophy (BPH)Prostatic Hyperplasia

Unknown Phase

WEUSKOP5723: Prostate Cancer Study

CompletedNCT01767363

GlaxoSmithKlineProstatic Hyperplasia

Start: 2012-11-30End: 2016-03-31Updated: 2016-11-09

Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

CompletedNCT07196280

Chinese PLA General HospitalAtherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)

Start: 2012-01-01End: 2022-12-31Target: 10000Updated: 2025-09-29